Free Trial
NASDAQ:COGT

Cogent Biosciences Q1 2025 Earnings Report

Cogent Biosciences logo
$10.85 +0.45 (+4.33%)
Closing price 04:00 PM Eastern
Extended Trading
$11.03 +0.18 (+1.66%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cogent Biosciences EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Cogent Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cogent Biosciences Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of next‐generation covalent inhibitors for the treatment of cancer. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cogent applies proprietary structure‐based drug design and covalent chemistry to identify small molecules that irreversibly bind key oncogenic targets. By leveraging covalent modality, the company aims to produce highly selective therapies capable of delivering deeper target engagement and prolonged pharmacodynamic effects in patients with advanced solid tumors and hematologic malignancies.

The company’s product pipeline includes multiple internally discovered candidates that inhibit validated cancer drivers. Among these are covalent inhibitors targeting mutant KRAS G12C, LSD1 demethylase, and other proteins involved in tumor growth and survival. Cogent’s lead program has advanced into early‐phase clinical trials, where it is being evaluated both as monotherapy and in combination with standard-of-care agents. Complementing its lead assets, the organization maintains preclinical programs in bacterial proteostasis and oncology, underscoring a broader ambition to address unmet medical needs through covalent drug candidates.

Cogent operates research laboratories in the Boston‐Cambridge biotech cluster and collaborates with academic institutions and contract research organizations to accelerate its discovery efforts. The company has established strategic partnerships to access specialized chemistry expertise and in vivo disease models, enabling rapid progression from hit identification to candidate nomination. While focused primarily on the U.S. market, Cogent is also exploring opportunities for global development and potential collaborations in Asia and Europe to broaden patient access.

Under the leadership of President and CEO Jim Sullivan and an experienced executive team drawn from leading pharmaceutical and biotechnology firms, Cogent Biosciences combines deep expertise in medicinal chemistry, structural biology, and translational oncology. The board of directors and scientific advisory committee include recognized experts in covalent pharmacology and cancer biology, positioning the company to advance its innovative pipeline toward the clinic and, ultimately, deliver new therapeutic options for patients with difficult‐to‐treat cancers.

View Cogent Biosciences Profile

More Earnings Resources from MarketBeat